Insmed (INSM) has issued an update.
Insmed Incorporated has announced new results from its ASPEN study, which evaluates the effectiveness and safety of the drug brensocatib for treating non-cystic fibrosis bronchiectasis. The findings, which add significant value to the company’s research, are set to be presented at the World Bronchiectasis Conference, highlighting potential advancements in the treatment of this chronic lung condition. These developments could be of considerable interest to investors tracking progress in the healthcare sector.
Find detailed analytics on INSM stock on TipRanks’ Stock Analysis page.
